Literature DB >> 34778800

Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

Kavita M Dhodapkar1,2,3, Madhav V Dhodapkar4,5,3, Akhilesh Kaushal6, Ajay K Nooka6,5, Allison R Carr6, Katherine E Pendleton2, Benjamin G Barwick6, Julia Manalo6, Samuel S McCachren6,3, Vikas A Gupta6,5, Nisha S Joseph6,5, Craig C Hofmeister6,5, Jonathan L Kaufman6,5, Leonard T Heffner6,5, Stephen M Ansell7, Lawrence H Boise6,5, Sagar Lonial6,5.   

Abstract

Waldenstrom macroglobulinemia (WM) and its precursor IgM gammopathy are distinct disorders characterized by clonal mature IgM-expressing B-cell outgrowth in the bone marrow. Here, we show by high-dimensional single-cell immunogenomic profiling of patient samples that these disorders originate in the setting of global B-cell compartment alterations, characterized by expansion of genomically aberrant extrafollicular B cells of the nonmalignant clonotype. Alterations in the immune microenvironment preceding malignant clonal expansion include myeloid inflammation and naïve B- and T-cell depletion. Host response to these early lesions involves clone-specific T-cell immunity that may include MYD88 mutation-specific responses. Hematopoietic progenitors carry the oncogenic MYD88 mutations characteristic of the malignant WM clone. These data support a model for WM pathogenesis wherein oncogenic alterations and signaling in progenitors, myeloid inflammation, and global alterations in extrafollicular B cells create the milieu promoting extranodal pattern of growth in differentiated malignant cells. SIGNIFICANCE: These data provide evidence that growth of the malignant clone in WM is preceded by expansion of extrafollicular B cells, myeloid inflammation, and immune dysfunction in the preneoplastic phase. These changes may be related in part to MYD88 oncogenic signaling in pre-B progenitor cells and suggest a novel model for WM pathogenesis. This article is highlighted in the In This Issue feature, p. 549. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34778800      PMCID: PMC8580616          DOI: 10.1158/2643-3230.BCD-21-0043

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN: 2643-3230


  56 in total

1.  The cellular origin and malignant transformation of Waldenström macroglobulinemia.

Authors:  Bruno Paiva; Luis A Corchete; Maria-Belen Vidriales; Ramón García-Sanz; Jose J Perez; Irene Aires-Mejia; Maria-Luz Sanchez; Paloma Barcena; Diego Alignani; Cristina Jimenez; Maria-Eugenia Sarasquete; María-Victoria Mateos; Enrique M Ocio; Noemi Puig; Fernando Escalante; José Hernández; Rebeca Cuello; Alfonso García de Coca; Magdalena Sierra; Maria-Carmen Montes; Tomás J González-López; Josefina Galende; Abelardo Bárez; José Alonso; Emilia Pardal; Alberto Orfao; Norma C Gutierrez; Jesús F San Miguel
Journal:  Blood       Date:  2015-02-05       Impact factor: 22.113

2.  VariantAnnotation: a Bioconductor package for exploration and annotation of genetic variants.

Authors:  Valerie Obenchain; Michael Lawrence; Vincent Carey; Stephanie Gogarten; Paul Shannon; Martin Morgan
Journal:  Bioinformatics       Date:  2014-03-28       Impact factor: 6.937

Review 3.  Mature lymphoid malignancies: origin, stem cells, and chronicity.

Authors:  Simon Husby; Kirsten Grønbæk
Journal:  Blood Adv       Date:  2017-11-28

4.  Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.

Authors:  M van Lohuizen; S Verbeek; P Krimpenfort; J Domen; C Saris; T Radaszkiewicz; A Berns
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

Review 5.  Extrafollicular responses in humans and SLE.

Authors:  Scott A Jenks; Kevin S Cashman; Matthew C Woodruff; F Eun-Hyung Lee; Ignacio Sanz
Journal:  Immunol Rev       Date:  2019-03       Impact factor: 12.988

Review 6.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

7.  Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.

Authors:  Radek Spisek; Anjli Kukreja; Lin-Chi Chen; Phillip Matthews; Amitabha Mazumder; David Vesole; Sundar Jagannath; Henry A Zebroski; Andrew J G Simpson; Gerd Ritter; Brian Durie; John Crowley; John D Shaughnessy; Matthew J Scanlan; Ali O Gure; Bart Barlogie; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

8.  The reactome pathway knowledgebase.

Authors:  Bijay Jassal; Lisa Matthews; Guilherme Viteri; Chuqiao Gong; Pascual Lorente; Antonio Fabregat; Konstantinos Sidiropoulos; Justin Cook; Marc Gillespie; Robin Haw; Fred Loney; Bruce May; Marija Milacic; Karen Rothfels; Cristoffer Sevilla; Veronica Shamovsky; Solomon Shorser; Thawfeek Varusai; Joel Weiser; Guanming Wu; Lincoln Stein; Henning Hermjakob; Peter D'Eustachio
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

9.  Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

10.  High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.

Authors:  Antonio Pezzutto; Antonia Busse; Özcan Çınar; Bernadette Brzezicha; Corinna Grunert; Peter Michael Kloetzel; Christin Beier; Caroline Anna Peuker; Ulrich Keller
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more
  2 in total

Review 1.  MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.

Authors:  Miguel Alcoceba; María García-Álvarez; Alejandro Medina; Rebeca Maldonado; Verónica González-Calle; María Carmen Chillón; María Eugenia Sarasquete; Marcos González; Ramón García-Sanz; Cristina Jiménez
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia.

Authors:  Julie R Gilbert; Himalee S Sabnis; Roman Radzievski; Deon B Doxie; Deborah DeRyckere; Sharon M Castellino; Kavita Dhodapkar
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.